What are the benefits of beta-blocker therapy in patients with NSTE-ACS?
Beta-blocker therapy has been shown to reduce mortality in patients with NSTE-ACS. It is recommended that oral beta-blocker therapy be initiated within the first 24 hours in patients who do not have any contraindications. In patients with concomitant NSTE-ACS, stabilized HF, and reduced systolic function, it is recommended to continue beta-blocker therapy with 1 of the 3 drugs proven to reduce mortality in patients with HF: sustained-release metoprolol succinate, carvedilol, or bisoprolol.